

XPHOZAH[®]

(tenapanor) tablets

The first and only FDA-approved Phosphate Absorption Inhibitor (PAI) that specifically blocks phosphorus absorption via the paracellular pathway with one pill BID

We invite you to join us for this presentation by leading nephrologists

A New Paradigm: Rethinking Hyperphosphatemia Management



Glenn M. Chertow
MD, MPH
Stanford University
School of Medicine
Stanford, CA



Steven Fishbane
MD
Northwell Health
Great Neck, NY

📅 **Saturday, March 9, 12:30PM ET**

Annual Dialysis Conference
Sheraton San Diego Hotel & Marina

Space is limited. RSVP here: <https://www.annualdialysisconference.org/ardelyx-luncheon-rsvp/>

INDICATION

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XPHOZAH is contraindicated in:

- Pediatric patients under 6 years of age
- Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

MOST COMMON ADVERSE REACTIONS

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see accompanying full Prescribing Information.

Reference: XPHOZAH[®] (tenapanor) full Prescribing Information. Waltham, MA: Ardelyx, Inc.; 2023.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, this program is intended only for healthcare professionals who will find its content clinically relevant to their practice. Accordingly, non-healthcare professionals (ie, spouses and other guests) may not attend. Invitation is extended only to those HCPs whose attendance would not violate compliance with state law requirements in which such HCP is licensed to practice.

